PSMA

Cat. No.

A41611

CAS No.

1366302-52-4

PSMA-11

Synonyms: HBED-CC-PSMA

PSMA-11 is a small molecule ligand that specifically targets and inhibits prostate-specific membrane antigen (PSMA). This compound is utilized in the synthesis of 68Ga-PSMA-11, a positron emission tomography (PET) tracer employed in the imaging of advanced prostate cancer. Its capabilities in targeting PSMA make it a valuable reagent for cancer research and diagnostic applications, particularly in understanding prostate cancer progression and treatment response.

Cat. No.

A41691

CAS No.

2577994-10-4

SC691

SC691 is a potent inhibitor of Prostate-Specific Membrane Antigen (PSMA), a key target in prostate cancer research. This compound can be labeled with 68Ga(III), facilitating effective imaging and diagnosis in prostate cancer. SC691 is essential for advancing diagnostic methodologies and therapeutic strategies in the study of prostate malignancies.

Cat. No.

A65427

CAS No.

2192281-54-0

Zadavotide guraxetan

Synonyms: PSMA I&T; PNT-2002

Zadavotide guraxetan is a potent inhibitor of prostate-specific membrane antigen (PSMA). This compound is utilized in SPECT/CT imaging, providing valuable insights into the cellular profiles of triple-negative breast cancer and prostate cancer. Its application in radionuclide studies underscores its significance in cancer research and therapeutic development.

Cat. No.

A65428

CAS No.

1025796-31-9

tert-Butyl-DCL

Synonyms: (OtBu)KuE(OtBu)2

Tert-Butyl-DCL is a potent inhibitor of Prostate-Specific Membrane Antigen (PSMA), a crucial target in prostate cancer research. Its inhibition of PSMA activity makes Tert-Butyl-DCL a valuable tool for studying the molecular mechanisms of prostate cancer progression and therapeutic interventions. This compound is ideal for applications in cancer biology and the development of PSMA-targeted therapies.

Cat. No.

A65435

CAS No.

1025796-32-0

GCPII-IN-1

GCPII-IN-1 is a potent inhibitor of the gene carboxypeptidase II (GCPII), also recognized as prostate-specific membrane antigen (PSMA), with a Ki value of 44.3 nM. This compound is primarily utilized in the research of prostate cancer, facilitating studies aimed at understanding tumor biology and developing potential therapeutic strategies. Its mechanism of action makes it a valuable tool for elucidating the role of GCPII in cancer progression.

Cat. No.

A65436

CAS No.

1269794-89-9

GCPII-IN-1 TFA

GCPII-IN-1 TFA is a selective inhibitor of GCPII (glutamate carboxypeptidase II), also known as prostate-specific membrane antigen (PSMA), exhibiting a Ki value of 44.3 nM. This compound is instrumental in the investigation of prostate cancer, facilitating studies on the modulation of GCPII activity and its potential therapeutic applications in oncology. Researchers can utilize GCPII-IN-1 TFA to explore mechanisms of tumor growth and treatment resistance in prostate cancer models.

Cat. No.

A65437

CAS No.

380225-52-5

Prostate Specific Antigen Substrate

Prostate Specific Antigen Substrate is a fluorescent substrate utilized for the detection of enzymatic activity associated with prostate specific antigen (PSA). This reagent enables researchers to effectively measure PSA activity, aiding in the study of prostate cancer and other related conditions. Its application in various assays facilitates enhanced understanding of PSA's role in oncology research.

Cat. No.

A65443

CAS No.

2703051-77-6

PSMA–DA1

PSMA–DA1 is a radioactive inhibitor targeting Prostate-Specific Membrane Antigen (PSMA). It serves as a promising radiotheranostic agent for imaging and treating PSMA-expressing tumors. Its specificity for PSMA makes it a valuable tool in the research of prostate cancer diagnosis and therapy, enabling the development of effective targeted treatment strategies.

Cat. No.

A65446

CAS No.

949575-20-6

MIP-1072

MIP-1072 is a selective inhibitor of prostate-specific membrane antigen (PSMA) that targets the enzyme's glutamate carboxypeptidase activity. With a Ki value of 4.6 nM, MIP-1072 demonstrates significant potency in inhibiting PSMA, making it a valuable tool in prostate cancer research. Its application is particularly relevant for studies focused on the role of PSMA in tumor progression and targeted therapies.

Cat. No.

A65450

CAS No.

949575-22-8

MIP-1095

Synonyms: RPS-001

MIP-1095 is a potent inhibitor of prostate-specific membrane antigen (PSMA), specifically targeting its glutamate carboxypeptidase activity with a Ki of 0.24 nM. This compound is valuable in research applications focused on prostate cancer, facilitating studies on PSMA's role in tumor progression and its potential as a therapeutic target. MIP-1095 is essential for the development of PSMA-targeted diagnostics and therapeutics.

Cat. No.

A65451

CAS No.

1561171-59-2

PSMA-IN-4

PSMA-IN-4 is a potent inhibitor of prostate-specific membrane antigen (PSMA), exhibiting an IC50 value of 1.2 μM. This compound effectively interferes with PSMA activity, making it a valuable tool in research focused on prostate cancer diagnostics and therapeutics. Its specificity and potency support investigations into PSMA's role in tumor biology and its potential as a therapeutic target.

Cat. No.

A65458

CAS No.

2946600-14-0

PSMA-IN-2

PSMA-IN-2 is a potent inhibitor of Prostate-Specific Membrane Antigen (PSMA) with a Ki value of 1.07 nM. This compound exhibits promising in vivo near-infrared (NIR) imaging properties at an emission wavelength of 1088 nm and an excitation wavelength of 808 nm. PSMA-IN-2 is particularly applicable in NIRII image-guided tumor resection surgeries in models of PSMA-positive tumors, making it a valuable tool for cancer research and therapeutic interventions.

Cat. No.

A65459

CAS No.

2941187-68-2

PSMA-IN-3

PSMA-IN-3 is a high-affinity inhibitor of Prostate-Specific Membrane Antigen (PSMA), demonstrating an IC50 value of 13 nM. This compound is particularly relevant for the development of 18F-labeled radioligands for positron emission tomography (PET) imaging to detect PSMA expression in prostate cancer. Researchers can utilize PSMA-IN-3 for studies aimed at advancing diagnostic imaging and therapeutic strategies in oncology.

Cat. No.

A65460

CAS No.

564482-79-7

DCFBC

DCFBC is a potent prostate-specific membrane antigen (PSMA) inhibitor, primarily utilized for small animal positron emission tomography (PET) imaging applications. Labeled with fluorine-18, [18F]DCFBC demonstrates preferential uptake in PSMA-expressing tumors, particularly in PIP tumors, while showing minimal uptake in FLU tumors. Additionally, while high accumulation in the kidneys and bladder is observed, the washout of radioactivity is faster compared to PIP tumors. This specificity positions [18F]DCFBC as a valuable tool for studying prostate cancer and assessing PSMA-targeted therapies.

Cat. No.

A65461

CAS No.

2647371-60-4

(R)-Zadavotide guraxetan

Synonyms: (R)-PSMA I&T; (R)-PNT-2002

(R)-Zadavotide guraxetan is a potent inhibitor of prostate-specific membrane antigen (PSMA), exhibiting significant antitumor activity. It is primarily utilized in research focused on prostate cancer, contributing to the understanding of targeted therapeutic approaches. This compound serves as a valuable tool for investigating the role of PSMA in cancer biology and evaluating efficacy in preclinical studies.

Cat. No.

A69590

CAS No.

5796-17-8

D-Dopa

Synonyms: 3-Hydroxy-D-tyrosine

D-Dopa (3-Hydroxy-D-tyrosine) is a potent, non-competitive allosteric inhibitor of glutamate carboxypeptidase II (GCPII), demonstrating an IC50 of 200 nM. This compound is known to elevate brain dopamine levels and induce turning behavior in rat models. Additionally, D-Dopa shows inhibitory effects against severe fever with thrombocytopenia syndrome (SFTS) virus infection. It serves as a valuable reagent for research applications in neurological diseases and viral infections.

Cat. No.

A69591

CAS No.

378242-00-3

E2072

E2072 is a selective, orally active competitive inhibitor of glutamate carboxypeptidase II (GCPII) with a Ki value of 10 nM. This compound has demonstrated efficacy in alleviating established thermal hyperalgesia in a rat model of chronic constriction injury. Additionally, E2072 has been shown to prevent oxaliplatin-induced reductions in nerve conduction velocity and amplitude in mice. It is suitable for research applications focused on neuropathic pain and neuropathy.

Cat. No.

A69596

CAS No.

373645-42-2

2-PMPA sodium

Synonyms: 2-(Phosphonomethyl)pentanedioic acid sodium

2-PMPA sodium is a potent inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 0.0003 μM. This compound effectively blocks the hydrolysis of N-acetylaspartylglutamate (NAAG), thereby modulating glutamate levels within the brain and influencing neurovascular coupling. Due to its specific action on GCPII, 2-PMPA sodium is valuable for investigating neurological diseases and understanding their underlying mechanisms. However, it is noted for its limited permeability across the blood-brain barrier, which may inform experimental design in related research.